135 related articles for article (PubMed ID: 10805521)
1. Coumarin-Ser-Asp-Lys-Pro-OH, a fluorescent substrate for determination of angiotensin-converting enzyme activity via high-performance liquid chromatography.
Cheviron N; Rousseau-Plasse A; Lenfant M; Adeline MT; Potier P; Thierry J
Anal Biochem; 2000 Apr; 280(1):58-64. PubMed ID: 10805521
[TBL] [Abstract][Full Text] [Related]
2. RXP 407, a selective inhibitor of the N-domain of angiotensin I-converting enzyme, blocks in vivo the degradation of hemoregulatory peptide acetyl-Ser-Asp-Lys-Pro with no effect on angiotensin I hydrolysis.
Junot C; Gonzales MF; Ezan E; Cotton J; Vazeux G; Michaud A; Azizi M; Vassiliou S; Yiotakis A; Corvol P; Dive V
J Pharmacol Exp Ther; 2001 May; 297(2):606-11. PubMed ID: 11303049
[TBL] [Abstract][Full Text] [Related]
3. Functional consequences of angiotensin-converting enzyme gene polymorphism on N-acetyl-Ser-Asp-Lys-Pro degradation and angiotensin II production.
Azizi M; Junot C; Ezan E; Hallouin MC; Guyene T; Ménard J
J Mol Med (Berl); 2002 Aug; 80(8):492-8. PubMed ID: 12185449
[TBL] [Abstract][Full Text] [Related]
4. In vivo assessment of captopril selectivity of angiotensin I-converting enzyme inhibition: differential inhibition of acetyl-ser-asp-lys-pro and angiotensin I hydrolysis.
Junot C; Menard J; Gonzales MF; Michaud A; Corvol P; Ezan E
J Pharmacol Exp Ther; 1999 Jun; 289(3):1257-61. PubMed ID: 10336514
[TBL] [Abstract][Full Text] [Related]
5. Antifibrotic peptide N-acetyl-Ser-Asp-Lys-Pro (Ac-SDKP): opportunities for angiotensin-converting enzyme inhibitor design.
Douglas RG; Ehlers MR; Sturrock ED
Clin Exp Pharmacol Physiol; 2013 Aug; 40(8):535-41. PubMed ID: 23351021
[TBL] [Abstract][Full Text] [Related]
6. Involvement of human plasma angiotensin I-converting enzyme in the degradation of the haemoregulatory peptide N-acetyl-seryl-aspartyl-lysyl-proline.
Rieger KJ; Saez-Servent N; Papet MP; Wdzieczak-Bakala J; Morgat JL; Thierry J; Voelter W; Lenfant M
Biochem J; 1993 Dec; 296 ( Pt 2)(Pt 2):373-8. PubMed ID: 8257427
[TBL] [Abstract][Full Text] [Related]
7. Combined use of selective inhibitors and fluorogenic substrates to study the specificity of somatic wild-type angiotensin-converting enzyme.
Jullien ND; Cuniasse P; Georgiadis D; Yiotakis A; Dive V
FEBS J; 2006 Apr; 273(8):1772-81. PubMed ID: 16623712
[TBL] [Abstract][Full Text] [Related]
8. Single-domain angiotensin I converting enzyme (kininase II): characterization and properties.
Deddish PA; Wang LX; Jackman HL; Michel B; Wang J; Skidgel RA; Erdös EG
J Pharmacol Exp Ther; 1996 Dec; 279(3):1582-9. PubMed ID: 8968386
[TBL] [Abstract][Full Text] [Related]
9. Determination of angiotensin converting enzyme inhibitory activity by high-performance liquid chromatography/electrospray-mass spectrometry.
Xiao X; Luo X; Chen B; Yao S
J Chromatogr B Analyt Technol Biomed Life Sci; 2006 Apr; 834(1-2):48-54. PubMed ID: 16513436
[TBL] [Abstract][Full Text] [Related]
10. Catabolism of the hemoregulatory peptide N-Acetyl-Ser-Asp-Lys-Pro: a new insight into the physiological role of the angiotensin-I-converting enzyme N-active site.
Rousseau-Plasse A; Lenfant M; Potier P
Bioorg Med Chem; 1996 Jul; 4(7):1113-9. PubMed ID: 8831983
[TBL] [Abstract][Full Text] [Related]
11. The hemoregulatory peptide N-acetyl-Ser-Asp-Lys-Pro is a natural and specific substrate of the N-terminal active site of human angiotensin-converting enzyme.
Rousseau A; Michaud A; Chauvet MT; Lenfant M; Corvol P
J Biol Chem; 1995 Feb; 270(8):3656-61. PubMed ID: 7876104
[TBL] [Abstract][Full Text] [Related]
12. Effect of angiotensin-converting enzyme inhibition on plasma, urine, and tissue concentrations of hemoregulatory peptide acetyl-Ser-Asp-Lys-Pro in rats.
Junot C; Nicolet L; Ezan E; Gonzales MF; Menard J; Azizi M
J Pharmacol Exp Ther; 1999 Dec; 291(3):982-7. PubMed ID: 10565814
[TBL] [Abstract][Full Text] [Related]
13. Catalytic properties of recombinant dipeptidyl carboxypeptidase from Escherichia coli: a comparative study with angiotensin I-converting enzyme.
Cunha CE; Magliarelli Hde F; Paschoalin T; Nchinda AT; Lima JC; Juliano MA; Paiva PB; Sturrock ED; Travassos LR; Carmona AK
Biol Chem; 2009 Sep; 390(9):931-40. PubMed ID: 19558329
[TBL] [Abstract][Full Text] [Related]
14. Substrate dependence of angiotensin I-converting enzyme inhibition: captopril displays a partial selectivity for inhibition of N-acetyl-seryl-aspartyl-lysyl-proline hydrolysis compared with that of angiotensin I.
Michaud A; Williams TA; Chauvet MT; Corvol P
Mol Pharmacol; 1997 Jun; 51(6):1070-6. PubMed ID: 9187274
[TBL] [Abstract][Full Text] [Related]
15. Determination of angiotensin I-converting enzyme activity in cell culture using fluorescence resonance energy transfer peptides.
Sabatini RA; Bersanetti PA; Farias SL; Juliano L; Juliano MA; Casarini DE; Carmona AK; Paiva AC; Pesquero JB
Anal Biochem; 2007 Apr; 363(2):255-62. PubMed ID: 17320031
[TBL] [Abstract][Full Text] [Related]
16. Performance of two commonly used angiotensin-converting enzyme inhibition assays using FA-PGG and HHL as substrates.
Shalaby SM; Zakora M; Otte J
J Dairy Res; 2006 May; 73(2):178-86. PubMed ID: 16476177
[TBL] [Abstract][Full Text] [Related]
17. Assessment of patients' and physicians' compliance to an ACE inhibitor treatment based on urinary N-acetyl Ser-Asp-Lys-Pro determination in the Noninsulin-Dependent Diabetes, Hypertension, Microalbuminuria, Proteinuria, Cardiovascular Events, and Ramipril (DIABHYCAR) study.
Azizi M; Ménard J; Peyrard S; Lièvre M; Marre M; Chatellier G
Diabetes Care; 2006 Jun; 29(6):1331-6. PubMed ID: 16732017
[TBL] [Abstract][Full Text] [Related]
18. Lisinopril, an angiotensin I-converting enzyme inhibitor, prevents entry of murine hematopoietic stem cells into the cell cycle after irradiation in vivo.
Rousseau-Plasse A; Wdzieczak-Bakala J; Lenfant M; Ezan E; Genet R; Robinson S; Briscoe T; Melville J; Riches A
Exp Hematol; 1998 Oct; 26(11):1074-9. PubMed ID: 9766448
[TBL] [Abstract][Full Text] [Related]
19. Positional-scanning combinatorial libraries of fluorescence resonance energy transfer peptides for defining substrate specificity of the angiotensin I-converting enzyme and development of selective C-domain substrates.
Bersanetti PA; Andrade MC; Casarini DE; Juliano MA; Nchinda AT; Sturrock ED; Juliano L; Carmona AK
Biochemistry; 2004 Dec; 43(50):15729-36. PubMed ID: 15595828
[TBL] [Abstract][Full Text] [Related]
20. Structural basis of Ac-SDKP hydrolysis by Angiotensin-I converting enzyme.
Masuyer G; Douglas RG; Sturrock ED; Acharya KR
Sci Rep; 2015 Sep; 5():13742. PubMed ID: 26403559
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
